BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-3. [PMID: 80682 DOI: 10.1016/s0140-6736(78)92644-2] [Cited by in Crossref: 634] [Cited by in F6Publishing: 681] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Fujii K, Shiohama T, Uchida T, Ikehara H, Fukuhara T, Sawada D, Aoyama H, Uchikawa H, Yoshii S, Arahata Y, Shimojo N, Misawa S, Kuwabara S. Nationwide survey of childhood Guillain-Barré syndrome, Fisher syndrome, and Bickerstaff brainstem encephalitis in Japan. Brain and Development 2023;45:16-25. [DOI: 10.1016/j.braindev.2022.09.007] [Reference Citation Analysis]
2 Pourbakhtyaran E, Heidari M, Akbari MG, Mohammadi M, Badv RS, Zamani G, Tavasoli AR, Rezaei Z, Mamishi S, Haji Esmaeil Memar E, Hosseiny SMM, Ghabeli H, Haghighi R, Ashrafi MR. Childhood Guillain-Barre syndrome in the SARS-CoV-2 era: Is there any causative relation? Clin Case Rep 2022;10:e6772. [PMID: 36545550 DOI: 10.1002/ccr3.6772] [Reference Citation Analysis]
3 Görgülü Ü, Geçer B, Bilen Ş, Kolcu G. Early Disability Predictors of Guillain–Barre Syndrome. SDÜ Tıp Fakültesi Dergisi 2022. [DOI: 10.17343/sdutfd.1188650] [Reference Citation Analysis]
4 Gupta A, Ranga A, Prakash NB, Khanna M. Rehabilitation outcomes in patients with post-COVID-19 vaccine-associated Guillain-Barre syndrome. JNRP 2022;0:1-7. [DOI: 10.25259/jnrp-2022-6-26] [Reference Citation Analysis]
5 Luijten LWG, Doets AY, Arends S, Dimachkie MM, Gorson KC, Islam B, Kolb NA, Kusunoki S, Papri N, Waheed W, Walgaard C, Yamagishi Y, Lingsma H, Jacobs BC; IGOS Consortium. Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2022:jnnp-2022-329937. [PMID: 36428088 DOI: 10.1136/jnnp-2022-329937] [Reference Citation Analysis]
6 Ginanneschi F, Cioncoloni D, Capoccitti G, Volpi N, Ferretti F, Giannini F, Rossi A. Study of total duration of distal compound muscle action potential in demyelinating and axonal Guillain-Barre’ syndrome. Neurological Research 2022. [DOI: 10.1080/01616412.2022.2148517] [Reference Citation Analysis]
7 Devi AK, Randhawa MS, Bansal A, Angurana SK, Malhi P, Nallasamy K, Jayashree M. Long-Term Neurological, Behavioral, Functional, Quality of Life, and School Performance Outcomes in Children With Guillain-Barré Syndrome Admitted to PICU. Pediatr Neurol 2022;140:18-24. [PMID: 36587490 DOI: 10.1016/j.pediatrneurol.2022.11.002] [Reference Citation Analysis]
8 Setia A, Bhatia J, Bhattacharya S. An Overview of Acute Flaccid Myelitis. CNSNDDT 2022;21:774-794. [DOI: 10.2174/1871527320666211125101424] [Reference Citation Analysis]
9 Pizzo F, Di Nora A, Di Mari A, Costanza G, Testa E, Strazzieri M, Greco F, Timpanaro T, Basile A, Belfiore G, Giugno A, Rocca R, Ruggieri M, Fiumara A, Pavone P. Case report: Incidence and prognostic value of brain MRI lesions and elevated cerebrospinal fluid protein in children with Guillain-Barré syndrome. Front Neurol 2022;13:885897. [DOI: 10.3389/fneur.2022.885897] [Reference Citation Analysis]
10 Peng Y, Luo M, Zhang Q. Elevated monocyte to high-density lipoprotein cholesterol ratio correlates with clinical severity in acute inflammatory demyelinating polyradiculoneuropathy patients. Front Neurol 2022;13:955933. [DOI: 10.3389/fneur.2022.955933] [Reference Citation Analysis]
11 Xu L, Gao TX, Chang SH, Jiang SM, Zhang LJ, Yang L. Role of lymphocyte-related immune-inflammatory biomarkers in detecting early progression of Guillain-Barré syndrome. J Clin Neurosci 2022;105:31-6. [PMID: 36063751 DOI: 10.1016/j.jocn.2022.08.017] [Reference Citation Analysis]
12 Harjpal P, Menon S, Kovela RK, Qureshi MI. Impact of Neuro Physiotherapeutic Reformation in a Teenager Agonizing With Guillain-Barre Syndrome Linked With COVID-19 Infection. Cureus 2022. [DOI: 10.7759/cureus.28650] [Reference Citation Analysis]
13 Zhang Y, Huang C, Lu W, Hu Q. Case Report: Delayed Guillain-Barré syndrome following trauma: A case series and manage considerations. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.903334] [Reference Citation Analysis]
14 Jin M, Liu K, Zhao L, Liu J, Zhao Z, Zhao Y, Sun S. Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barré syndrome. Front Neurol 2022;13:972367. [DOI: 10.3389/fneur.2022.972367] [Reference Citation Analysis]
15 Kong L, Wu X, Cheng Y, Liu S, Liu K, Li C. The prediction effects of thyroid function in the severity of Guillain-Barré syndrome. Neurol Sci 2022;43:5017-5028. [DOI: 10.1007/s10072-022-06070-3] [Reference Citation Analysis]
16 Ding Y, Wang L, Sun J, Shi Y, Li G, Luan X, Zheng G, Zhang G. Remnant Cholesterol and Dyslipidemia Are Risk Factors for Guillain–Barré Syndrome and Severe Guillain–Barré Syndrome by Promoting Monocyte Activation. Front Immunol 2022;13:946825. [DOI: 10.3389/fimmu.2022.946825] [Reference Citation Analysis]
17 Fokkink WJR, van Tilburg SJ, de Winter BCM, Sassen SDT, van Doorn PA, Koch BCP, Jacobs BC. Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome. Clin Pharmacokinet 2022. [PMID: 35781631 DOI: 10.1007/s40262-022-01136-z] [Reference Citation Analysis]
18 Tamborska AA, Singh B, Leonhard SE, Hodel EM, Stowe J, Watson-fargie T, Fernandes PM, Themistocleous AC, Roelofs J, Brennan K, Morrice C, Michael BD, Jacobs BC, Mcdonald H, Solomon T. Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. BMJ Neurol Open 2022;4:e000309. [DOI: 10.1136/bmjno-2022-000309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ginanneschi F, Giannini F, Sicurelli F, Battisti C, Capoccitti G, Bartalini S, Mignarri A, Volpi N, Cioncoloni D, Franci L, De Stefano N, Rossi A. Clinical Features and Outcome of the Guillain–Barre Syndrome: A Single-Center 11-Year Experience. Front Neurol 2022;13:856091. [DOI: 10.3389/fneur.2022.856091] [Reference Citation Analysis]
20 do Rosário MS, de Jesus PAP, Farias DS, Novaes MAC, Francisco MVLO, Santos CS, Moura D, Lima FWDM, Alcantara LCJ, de Siqueira IC. Guillain-Barré Syndrome and Miller Fisher Syndrome in Association With an Arboviral Outbreak: A Brazilian Case Series. Front Med 2022;9:911175. [DOI: 10.3389/fmed.2022.911175] [Reference Citation Analysis]
21 Jin M, Liu J, Zhao Z, Geng W, Sun S. Association Between A-Waves and Outcome in Pediatric Guillain-Barré Syndrome. Front Neurol 2022;13:914048. [DOI: 10.3389/fneur.2022.914048] [Reference Citation Analysis]
22 Hayat S, Asad A, Hasan I, Jahan I, Papri N, Howlader ZH, Islam Z. Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barré syndrome. Acta Neurol Scand 2022. [PMID: 35652365 DOI: 10.1111/ane.13649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Wang S, Luo Z, Peng T. Serum thyroid-stimulating hormone is an independent risk factor of recurrent Guillain-Barré syndrome. Muscle Nerve 2022;65:688-92. [PMID: 35342963 DOI: 10.1002/mus.27539] [Reference Citation Analysis]
24 López-Hernández JC, Jorge de Saráchaga A, Briseño-Godínez ME, May-Mas RN, Bazán-Rodríguez L, León-Manriquez E, Cruz-Pérez J, Becerra-Hernández I, Vargas-Cañas ES. Deltoid Muscle Strength and Autonomic Dysfunction as Independent Risk Factors for Invasive Mechanical Ventilation in Patients with Guillain-Barré Syndrome. Int J Neurosci 2022;:1-13. [PMID: 35633066 DOI: 10.1080/00207454.2022.2082963] [Reference Citation Analysis]
25 Štětkářová I, Ehler E, Židó M, Lauer D, Polák J, Keller J, Peisker T. Influence of Hyperglycaemia and CRP on the Need for Mechanical Ventilation in Guillain-Barré Syndrome. Front Neurol 2022;13:875714. [DOI: 10.3389/fneur.2022.875714] [Reference Citation Analysis]
26 Nikolaus M, Kühne F, Tietze A, Thumfart J, Kempf C, Gratopp A, Knierim E, Bittigau P, Kaindl AM. Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders. J Child Neurol 2022;37:505-16. [PMID: 35435761 DOI: 10.1177/08830738221089476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 García-grimshaw M, Galnares-olalde JA, Bello-chavolla OY, Michel-chávez A, Cadena-fernández A, Briseño-godínez ME, Antonio-villa NE, Nuñez I, Gutiérrez-romero A, Hernández-vanegas L, del Mar Saniger-alba M, Carrillo-mezo R, Ceballos-liceaga SE, Carbajal-sandoval G, Flores-silva FD, Díaz-ortega JL, López-gatell H, Cortes-alcalá R, Pérez-padilla JR, Chiquete E, Reyes-terán G, Arauz A, Valdés-ferrer SI. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines.. [DOI: 10.1101/2022.04.11.22273754] [Reference Citation Analysis]
28 Jahan I, Hayat S, Khalid MM, Ahammad RU, Asad A, Islam B, Mohammad QD, Jacobs BC, Islam Z. Association of mannose-binding lectin 2 gene polymorphisms with Guillain-Barré syndrome. Sci Rep 2022;12:5791. [PMID: 35388043 DOI: 10.1038/s41598-022-09621-y] [Reference Citation Analysis]
29 Ergin Beton O, Ozturk Tan O, Bilen S. The potential association between COVID-19 disease and Guillain-Barré syndrome. Neurol Res 2022;:1-6. [PMID: 35348038 DOI: 10.1080/01616412.2022.2056342] [Reference Citation Analysis]
30 Ohnmar O, Hlaing KP, Win ZN, Aung YL, Tun Z, Htay KOK, Thit WM, Umapathi T. Guillain‐Barré syndrome (GBS) in a tertiary general hospital at Yangon, Myanmar. Neurology & Clinical Neurosc 2022;10:72-77. [DOI: 10.1111/ncn3.12579] [Reference Citation Analysis]
31 Arnold LM, Hehir MK, Tandan R, Kolb N, Waheed W. Neck Flexion Strength as a Predictor of Need for Intubation in Guillain-Barre Syndrome. J Clin Neuromuscul Dis 2022;23:119-23. [PMID: 35188907 DOI: 10.1097/CND.0000000000000365] [Reference Citation Analysis]
32 Alessandro L, Castiglione JI, Brand P, Bruno V, Barroso F. Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence. Arq Neuropsiquiatr 2022:S0004-282X2022005003213. [PMID: 35195232 DOI: 10.1590/0004-282X-ANP-2021-0226] [Reference Citation Analysis]
33 Hiew FL, Thit WM, Alexander M, Thirugnanam U, Siritho S, Tan K, Mya Aye SM, Ohnmar O, Estiasari R, Yassin N, Pasco PM, Keosodsay SS, Trong Nghia HT, Islam MB, Wong SK, Lee S, Chhabra A, Viswanathan S. Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium. J Cent Nerv Syst Dis 2021;13:11795735211057314. [PMID: 35173510 DOI: 10.1177/11795735211057314] [Reference Citation Analysis]
34 Charoentanyarak K, Singjam A, Saengsuwan J. Clinical predictors and electrodiagnostic characteristics in patients with Guillain-Barré syndrome with respiratory failure: a retrospective, matched case-control study. PeerJ 2022;10:e12930. [PMID: 35186497 DOI: 10.7717/peerj.12930] [Reference Citation Analysis]
35 Ma L, Liu S, Xiao Z, Guan J, Liu Y, Yao J, Lu Z. Comparison of the effects of different doses of Glucocorticoids on distinct subtypes of Guillain-Barré syndrome in Southern China. BMC Neurol 2022;22. [DOI: 10.1186/s12883-022-02567-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Islam B, Islam Z, Endtz HP, Jahan I, Jacobs BC, Mohammad QD, Franssen H. Electrophysiology of Guillain-Barré syndrome in Bangladesh: A prospective study of 312 patients. Clin Neurophysiol Pract 2021;6:155-63. [PMID: 35112034 DOI: 10.1016/j.cnp.2021.03.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Althubaiti F, Guiomard C, Rivier F, Meyer P, Leboucq N. Prognostic value of contrast-enhanced MRI in Guillain-Barré syndrome in children. Arch Pediatr 2022:S0929-693X(22)00014-8. [PMID: 35101331 DOI: 10.1016/j.arcped.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Davidson I, Parker ZJ. Falls in people post-Guillain-Barré syndrome in the United Kingdom: A national cross-sectional survey of community based adults. Health Soc Care Community 2022. [PMID: 35015326 DOI: 10.1111/hsc.13703] [Reference Citation Analysis]
39 Ali Shalash, Nourhan Belal, Amr S. Zaki, Shady S. Georgy, Mohamed Fahmy Doheim, Ahmed Hazzou, Azza Abdelnasser. Guillain–Barré syndrome following different COVID-19 vaccines: a case series. Egypt J Neurol Psychiatr Neurosurg 2022;58:153. [ DOI: 10.1186/s41983-022-00582-7] [Reference Citation Analysis]
40 Arends S, Drenthen J, van den Bergh P, Franssen H, Hadden RD, Islam B, Kuwabara S, Reisin RC, Shahrizaila N, Amino H, Antonini G, Attarian S, Balducci C, Barroso F, Bertorini T, Binda D, Brannagan TH, Buermann J, Casasnovas C, Cavaletti G, Chao C, Dimachkie MM, Fulgenzi EA, Galassi G, Gutiérrez Gutiérrez G, Harbo T, Hartung H, Hsieh S, Kiers L, Lehmann HC, Manganelli F, Marfia GA, Mataluni G, Pardo J, Péréon Y, Rajabally YA, Santoro L, Sekiguchi Y, Stein B, Stettner M, Uncini A, Verboon C, Verhamme C, Vytopil M, Waheed W, Wang M, Zivkovic S, Jacobs BC, Cornblath DR. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology 2022. [DOI: 10.1016/j.clinph.2021.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Meshram B, Shrikrishna R, Mahapatra A. Management of guillain-barre syndrome in a child through ayurveda intervention – A case study. J Ayurveda 2022;16:334. [DOI: 10.4103/joa.joa_185_22] [Reference Citation Analysis]
42 Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, Attarian S, Benedetti L, Briani C, Casasnovas C, Castellani F, Dardiotis E, Echaniz-Laguna A, Garssen MPJ, Harbo T, Huizinga R, Humm AM, Jellema K, van der Kooi AJ, Kuitwaard K, Kuntzer T, Kusunoki S, Lascano AM, Martinez-Hernandez E, Rinaldi S, Samijn JPA, Scheidegger O, Tsouni P, Vicino A, Visser LH, Walgaard C, Wang Y, Wirtz PW, Ripellino P, Jacobs BC; IGOS consortium. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 2021;144:3392-404. [PMID: 34553216 DOI: 10.1093/brain/awab279] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
43 Boedecker SC, Luessi F, Engel S, Kraus D, Klimpke P, Holtz S, Meinek M, Marczynski P, Weinmann A, Weinmann-Menke J. Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases. J Clin Apher 2021. [PMID: 34904748 DOI: 10.1002/jca.21953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Ždraljević M, Radišić V, Perić S, Kačar A, Jovanović D, Berisavac I. Guillain-Barré syndrome during pregnancy: A case series. J Obstet Gynaecol Res 2021. [PMID: 34850502 DOI: 10.1111/jog.15116] [Reference Citation Analysis]
45 Jin M, Zhao L, Liu J, Geng W, Zhao Z, Li C, Xue J, Sun S. Association Between the Rate of Treatment Response and Short-Term Outcomes in Childhood Guillain-Barré Syndrome. Front Neurol 2021;12:746389. [PMID: 34803884 DOI: 10.3389/fneur.2021.746389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Helfferich J, Roodbol J, de Wit MC, Brouwer OF, Jacobs BC; 2016 Enterovirus D68 Acute Flaccid Myelitis Working Group and the Dutch Pediatric GBS Study Group. Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria. Eur J Neurol 2021. [PMID: 34747551 DOI: 10.1111/ene.15170] [Reference Citation Analysis]
47 Stojanov A, Basta I, Berisavac I, Stojiljkovic-Tamas O, Bozovic I, Arsenijevic M, Palibrk A, Peric S. Responsiveness of 2 Different Ability Outcome Measures in Guillain-Barré Syndrome. Neurologist 2021;26:244-7. [PMID: 34734901 DOI: 10.1097/NRL.0000000000000341] [Reference Citation Analysis]
48 Lleixà C, Martín-Aguilar L, Pascual-Goñi E, Franco T, Caballero M, de Luna N, Gallardo E, Suárez-Calvet X, Martínez-Martínez L, Diaz-Manera J, Rojas-García R, Cortés-Vicente E, Turón J, Casasnovas C, Homedes C, Gutiérrez-Gutiérrez G, Jimeno-Montero MC, Berciano J, Sedano-Tous MJ, García-Sobrino T, Pardo-Fernández J, Márquez-Infante C, Rojas-Marcos I, Jericó-Pascual I, Martínez-Hernández E, Morís de la Tassa G, Domínguez-González C, Juárez C, Illa I, Querol L. Autoantibody screening in Guillain-Barré syndrome. J Neuroinflammation 2021;18:251. [PMID: 34719386 DOI: 10.1186/s12974-021-02301-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 da Silva GF, da Silva CF, Oliveira RENDN, Romancini F, Mendes RM, Locks A, Longo MFM, Moro CHC, Longo AL, Braatz VL. Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association. Clin Exp Neuroimmunol 2021. [PMID: 34900000 DOI: 10.1111/cen3.12678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
50 Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis. Medicine (Baltimore) 2021;100:e27351. [PMID: 34731107 DOI: 10.1097/MD.0000000000027351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
51 Briseño-Godínez ME, Arauz A, López-Hernández JC, de Saráchaga AJ, Pérez-Valdez EY, May-Más RN, López-Hernández G, Bazán-Rodriguez L, Galnares-Olalde JA, León-Manríquez E, Vargas-Cañas ES. Prognostic Factors in Elderly Patients With Guillain-Barré Syndrome: Does Age Matter? Neurohospitalist 2021;11:303-9. [PMID: 34567390 DOI: 10.1177/19418744211002676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, Zimprich F. Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades. Sci Rep 2021;11:19170. [PMID: 34580356 DOI: 10.1038/s41598-021-98501-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Leonhard SE, Tan CY, van der Eijk AA, Reisin RR, Franken SC, Huizinga R, Arends S, Batstra MR, Bezerra Jeronimo SM, Drenthen J, de Koning L, Leon Cejas L, Marchesoni C, Marques W Jr, Shahrizaila N, Casas DF, Sotelo A, Tillard B, Dourado ME, Jacobs BC. Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission: A multinational case-control study. J Peripher Nerv Syst 2021;26:449-60. [PMID: 34549484 DOI: 10.1111/jns.12469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Kumar M, Kalita J, Kant Misra U, Dhar N. Prediction models for mechanical ventilation and outcome in Guillain-Barré syndrome. J Clin Neurosci 2021;92:131-5. [PMID: 34509240 DOI: 10.1016/j.jocn.2021.07.060] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Krause K, Wulf M, Sommer P, Barkovits K, Vorgerd M, Marcus K, Eggers B. CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. Diagnostics (Basel) 2021;11:1522. [PMID: 34573864 DOI: 10.3390/diagnostics11091522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Halani S, Tombindo PE, O'Reilly R, Miranda RN, Erdman LK, Whitehead C, Bielecki JM, Ramsay L, Ximenes R, Boyle J, Krueger C, Willmott S, Morris SK, Murphy KE, Sander B. Clinical manifestations and health outcomes associated with Zika virus infections in adults: A systematic review. PLoS Negl Trop Dis 2021;15:e0009516. [PMID: 34252102 DOI: 10.1371/journal.pntd.0009516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Wen P, Wang L, Liu H, Gong L, Ji H, Wu H, Chu W. Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome. Sci Rep 2021;11:11578. [PMID: 34079013 DOI: 10.1038/s41598-021-91132-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
58 Xie J, Zhang T, Liu T. First report of Bickerstaff's brainstem encephalitis caused by Salmonella Dublin: a case report. BMC Neurol 2021;21:199. [PMID: 33992070 DOI: 10.1186/s12883-021-02230-8] [Reference Citation Analysis]
59 Lleixà C, Martín-aguilar L, Pascual-goñi E, Franco T, Caballero M, Diaz-manera J, Rojas-garcía R, de Luna N, Gallardo E, Cortés-vicente E, Turón J, Suárez-calvet X, Casasnovas C, Homedes C, Gutiérrez-gutiérrez G, Jimeno-montero MC, Berciano J, Sedano Tous MJ, Garcia-sobrino T, Pardo-fernandez J, Márquez-infante C, Rojas-marcos I, Jericó-pascual I, Martínez-hernández E, Morís de la Tassa G, Domínguez-gonzález C, Martínez-martínez L, Juárez C, Illa I, Querol L. Autoantibody screening in Guillain-Barré Syndrome.. [DOI: 10.1101/2021.05.10.21256964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Dhar N, Madhaw G, Kumar M, Kumar N, Tiwari A, Jatale V. Non-COVID Neurological Emergencies: A Silent Killer Going Unnoticed during COVID-19 Pandemic. J Neurosci Rural Pract 2021;12:461-9. [PMID: 34295099 DOI: 10.1055/s-0040-1722810] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Harbo T, Andersen H. Neuromuscular Effects and Rehabilitation in Guillain-Barré Syndrome Associated with Zika Virus Infection. Current Concepts in Zika Research 2021. [DOI: 10.5772/intechopen.93930] [Reference Citation Analysis]
62 Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care 2020;32:113-20. [PMID: 31297663 DOI: 10.1007/s12028-019-00781-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
63 Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, Van Doorn PA, Dourado ME, Hughes RA, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Diretrizes Baseadas em Evidências Diagnóstico e manejo da Síndrome de Guillain–Barré em dez etapas. Rev Neurocienc 2021;29:1-52. [DOI: 10.34024/rnc.2021.v29.11725] [Reference Citation Analysis]
64 Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Castañeda CC, Dioses JA, Tipismana MA, Abanto JT, Llanos A, Gourlay D, Grogl M, Ramos M, Rojas JD, Meza R, Puiu D, Sherman RM, Salzberg SL, Simner PJ, Willison HJ, Jacobs BC, Cornblath DR, Umeres HF, Pardo CA. Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection. Neurol Neuroimmunol Neuroinflamm 2021;8:e952. [PMID: 33547152 DOI: 10.1212/NXI.0000000000000952] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
65 Drenthen J, Islam B, Islam Z, Mohammad QD, Maathuis EM, Visser GH, van Doorn PA, Blok JH, Endtz HP, Jacobs BC. Changes in motor nerve excitability in acute phase Guillain-Barré syndrome. Muscle Nerve 2021;63:546-52. [PMID: 33452679 DOI: 10.1002/mus.27172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Gong Q, Liu S, Liu Y, Yao J, Fu X, Xiao Z, Lu Z. Guillain-Barré syndrome triggered by surgery in a Chinese population: a multicenter retrospective study. BMC Neurol 2021;21:40. [PMID: 33509120 DOI: 10.1186/s12883-021-02067-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Stoian A, Șerban G, Bajko Z, Andone S, Mosora O, Bălașa A. Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review). Exp Ther Med 2021;21:265. [PMID: 33603872 DOI: 10.3892/etm.2021.9696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Harbo T, Andersen H. Neuromuscular effects and rehabilitation in Guillain-Barré syndrome. Zika Virus Impact, Diagnosis, Control, and Models 2021. [DOI: 10.1016/b978-0-12-820267-8.00013-3] [Reference Citation Analysis]
69 Kesici S, Bayrakci B. Severe Guillain-Barré syndrome. Zika Virus Impact, Diagnosis, Control, and Models 2021. [DOI: 10.1016/b978-0-12-820267-8.00011-x] [Reference Citation Analysis]
70 References. Child Neurology 2021. [DOI: 10.1016/b978-0-12-821635-4.00271-x] [Reference Citation Analysis]
71 Soto-hernández JL, Loza KC, Cañas SV. A case study of Guillain-Barre syndrome associated with Zika virus infection. Zika Virus Impact, Diagnosis, Control, and Models 2021. [DOI: 10.1016/b978-0-12-820267-8.00018-2] [Reference Citation Analysis]
72 Wijdicks EFM. Scales and Scores. Examining Neurocritical Patients 2021. [DOI: 10.1007/978-3-030-69452-4_2] [Reference Citation Analysis]
73 Satkowiak K, Smith AG. Guillain-Barré Syndrome. Emergency Neurology 2021. [DOI: 10.1007/978-3-030-75778-6_12] [Reference Citation Analysis]
74 Chang SH, Tian XB, Wang J, Liu MQ, Huang CN, Qi Y, Zhang LJ, Gao CL, Zhang DQ, Sun LS, Yang L. Increased Cerebrospinal Fluid Uric Acid Levels in Guillain-Barré Syndrome. Front Neurol 2020;11:589928. [PMID: 33281729 DOI: 10.3389/fneur.2020.589928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Hegen H, Ladstätter F, Bsteh G, Auer M, Berek K, Di Pauli F, Walde J, Wanschitz J, Zinganell A, Deisenhammer F. Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. Eur J Neurol 2021;28:965-73. [PMID: 33073472 DOI: 10.1111/ene.14600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
76 Ning P, Yang B, Yang X, Zhao Q, Huang H, Shen Q, Lu H, Tian S, Xu Y. A nomogram to predict mechanical ventilation in Guillain-Barré syndrome patients. Acta Neurol Scand 2020;142:466-74. [PMID: 32497277 DOI: 10.1111/ane.13294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
77 Tu Y, Gong X, Zeng G, Zhuo W, Li Z, Yu X. Differences in Thyroid Function and Autoantibodies in the Development of Guillain-Barré Syndrome vs. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Front Neurol 2020;11:1018. [PMID: 33013669 DOI: 10.3389/fneur.2020.01018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Young J. Ankle-Foot Orthoses Improve Standing and Walking in Severe Guillain-Barré Syndrome: A Case Report. J Prosthet Orthot 2020;32:319-323. [DOI: 10.1097/jpo.0000000000000338] [Reference Citation Analysis]
79 Yoshikawa K, Kuwahara M, Morikawa M, Kusunoki S. Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. Neurol Neuroimmunol Neuroinflamm 2020;7:e889. [PMID: 32934014 DOI: 10.1212/NXI.0000000000000889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
80 Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain-Barre Syndrome: a network meta-analysis.. [DOI: 10.1101/2020.06.03.20121780] [Reference Citation Analysis]
81 Hayat S, Babu G, Das A, Howlader ZH, Mahmud I, Islam Z. Fc-gamma IIIa-V158F receptor polymorphism contributes to the severity of Guillain-Barré syndrome. Ann Clin Transl Neurol 2020;7:1040-9. [PMID: 32484314 DOI: 10.1002/acn3.51072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Hosokawa T, Nakajima H, Sawai T, Nakamura Y, Sano E, Tsukahara A, Unoda K, Ishida S, Sakane S, Kimura F, Arawaka S. Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels. BMC Neurol 2020;20:214. [PMID: 32460711 DOI: 10.1186/s12883-020-01796-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Finneran MM, Gaynor B, Omi E. Guillain-Barré Syndrome After a Gunshot Wound to the Thoracic Spine. World Neurosurg 2020;139:175-8. [PMID: 32311568 DOI: 10.1016/j.wneu.2020.04.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Bao L, Chen X, Li Q, Zhang R, Shi H, Cui G. Surgery and Guillain-Barré Syndrome: A Single-Center Retrospective Study Focused on Clinical and Electrophysiological Subtypes. Neuropsychiatr Dis Treat 2020;16:969-74. [PMID: 32346291 DOI: 10.2147/NDT.S241128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
85 Martín-aguilar L, Camps-renom P, Lleixà C, Pascual-goñi E, Diaz-manera J, Rojas-garcía R, de Luna N, Gallardo E, Cortés-vicente E, Muñoz L, Alcolea D, Lleó A, Casasnovas C, Homedes C, Gutiérrez-gutiérrez G, Jimeno-montero MC, Berciano J, Sedano Tous MJ, Garcia-sobrino T, Pardo-fernandez J, Márquez-infante C, Rojas-marcos I, Pascual IJ, Martínez-hernández E, de la Tassa GM, Domínguez-gonzález C, Illa I, Querol L. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.. [DOI: 10.1101/2020.03.24.20042200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
86 Yang L, Zhao X. Integrated Chinese and Western Medicine for Acute Guillain-barré Syndrome Treatment. Transl Neurosci 2020;11:38-47. [PMID: 32161685 DOI: 10.1515/tnsci-2020-0007] [Reference Citation Analysis]
87 Djordjevic G, Stojanov A, Bozovic I, Berisavac I, Arsenijevic M, Lukic Rajic S, Dominovic Kovacevic A, Jovanovic D, Basta I, Peric S. Six-month prospective study of quality of life in Guillain-Barre syndrome. Acta Neurol Scand 2020;141:236-41. [PMID: 31705530 DOI: 10.1111/ane.13195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
88 Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2020;1:CD008630. [PMID: 31981368 DOI: 10.1002/14651858.CD008630.pub5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
89 Muniyandy S, Janarthanan P, Sathasivam T. AlCl<sub>3</sub> Cross-Linked and Spray Dried Carboxymethyl Sago Cellulose Microspheres as Potential Carriers for the Enteric Delivery. MSCE 2020;08:21-31. [DOI: 10.4236/msce.2020.810003] [Reference Citation Analysis]
90 Cheng MCF, Murphy PB, Hart N, Evans MRB, Spillane JE, Howard RS. Prolonged Ventilatory Support for Patients Recovering From Guillain-Barré Syndrome. Neurol Clin Pract 2021;11:18-24. [PMID: 33968468 DOI: 10.1212/CPJ.0000000000000793] [Reference Citation Analysis]
91 Tunç A. Early predictors of functional disability in Guillain-Barré Syndrome. Acta Neurol Belg 2019;119:555-9. [PMID: 30963477 DOI: 10.1007/s13760-019-01133-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
92 Bourque PR, Brooks J, Warman-Chardon J, Breiner A. Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology. J Neurol 2020;267:746-51. [PMID: 31734909 DOI: 10.1007/s00415-019-09634-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
93 Ogata H, Zhang X, Yamasaki R, Fujii T, Machida A, Morimoto N, Kaida K, Masuda T, Ando Y, Kuwahara M, Kusunoki S, Nakamura Y, Matsushita T, Isobe N, Kira JI. Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody. Ann Clin Transl Neurol 2019;6:2304-16. [PMID: 31657126 DOI: 10.1002/acn3.50931] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
94 Bazaraa HM, Rady HI, Mohamed SA, Rabie WA, ElAnwar NH. Initial Response and Outcome of Critically Ill Children With Guillain Barre' Syndrome. Front Pediatr 2019;7:378. [PMID: 31620410 DOI: 10.3389/fped.2019.00378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
95 Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, Colon-Sanchez C, Garcia M, Olivero-Segarra M, Malave G, Rodríguez-Vega GM, Thomas DL, Waterman SH, Sejvar JJ, Luciano CA, Sharp TM, Rivera-García B. Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016. JAMA Neurol 2018;75:1089-97. [PMID: 29799940 DOI: 10.1001/jamaneurol.2018.1058] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
96 Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, van Doorn PA, Dourado ME, Hughes RAC, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019;15:671-83. [PMID: 31541214 DOI: 10.1038/s41582-019-0250-9] [Cited by in Crossref: 250] [Cited by in F6Publishing: 266] [Article Influence: 62.5] [Reference Citation Analysis]
97 Svačina MKR, Röth P, Bobylev I, Sprenger A, Zhang G, Sheikh KA, Lehmann HC. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome. J Neuroimmune Pharmacol 2019;14:642-8. [PMID: 31515689 DOI: 10.1007/s11481-019-09871-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
98 Li C, Luo T, Cheng Y, Liu S, Qiao L, Wu X, Liu K. The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome. Neurol Sci 2020;41:295-303. [PMID: 31494821 DOI: 10.1007/s10072-019-04063-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
99 Khanna M, Rawat N, Gupta A, Nagappa M, Taly AB, Rukmani MR, Sathyaprabha TN, Haldar P. Pulmonary Involvement in Patients with Guillain-Barré Syndrome in Subacute Phase. J Neurosci Rural Pract 2017;8:412-6. [PMID: 28694622 DOI: 10.4103/jnrp.jnrp_11_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
100 Mehta VK, Verma R, Garg RK, Malhotra HS, Sharma PK, Jain A. Study of interleukin-6 and interleukin-8 levels in patients with neurological manifestations of dengue. J Postgrad Med 2017;63:11-5. [PMID: 28079042 DOI: 10.4103/0022-3859.188545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
101 Walteros DM, Soares J, Styczynski AR, Abrams JY, Galindo-Buitrago JI, Acosta-Reyes J, Bravo-Ribero E, Arteta ZE, Solano-Sanchez A, Prieto FE, Gonzalez-Duarte M, Navarro-Lechuga E, Salinas JL, Belay ED, Schonberger LB, Damon IK, Ospina ML, Sejvar JJ. Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection. PLoS One 2019;14:e0220049. [PMID: 31369576 DOI: 10.1371/journal.pone.0220049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
102 Carrera-García L, Natera-de Benito D, Lleixà C, Ortez C, Colomer J, Nascimento A, Saiz A, Dalmau J, Querol L, Armangué T. Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurol Neuroimmunol Neuroinflamm 2019;6:e602. [PMID: 31454775 DOI: 10.1212/NXI.0000000000000602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
103 Tian J, Cao C, Li T, Zhang K, Li P, Liu Y, Liu X. Electrophysiological Subtypes and Prognostic Factors of Guillain-Barre Syndrome in Northern China. Front Neurol 2019;10:714. [PMID: 31333568 DOI: 10.3389/fneur.2019.00714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
104 Soto-Hernández JL, Ponce de León Rosales S, Vargas Cañas ES, Cárdenas G, Carrillo Loza K, Díaz-Quiñonez JA, López-Martínez I, Jiménez-Corona ME, Ruiz-Matus C, Kuri Morales P. Guillain-Barré Syndrome Associated With Zika Virus Infection: A Prospective Case Series From Mexico. Front Neurol 2019;10:435. [PMID: 31114537 DOI: 10.3389/fneur.2019.00435] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
105 Koga M, Kishi M, Fukusako T, Ikuta N, Kato M, Kanda T. Antecedent infections in Fisher syndrome: sources of variation in clinical characteristics. J Neurol 2019;266:1655-62. [PMID: 30955122 DOI: 10.1007/s00415-019-09308-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
106 Bölükbaşi F, Ersen G, Gündüz A, Karaali-Savrun F, Yazici S, Uzun N, Akalin MA, Kiziltan ME. Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors. Noro Psikiyatr Ars 2019;56:71-4. [PMID: 30911241 DOI: 10.5152/npa.2017.18091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Heming M, Schulte-Mecklenbeck A, Brix T, Wolbert J, Ruland T, Klotz L, Meuth SG, Gross CC, Wiendl H, Meyer Zu Hörste G. Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. Front Immunol 2019;10:515. [PMID: 30984164 DOI: 10.3389/fimmu.2019.00515] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
108 Shi M, Zhu J, Deng H. Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome. Front Neurol 2019;10:225. [PMID: 30930839 DOI: 10.3389/fneur.2019.00225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
109 Islam Z, Papri N, Ara G, Ishaque T, Alam AU, Jahan I, Islam B, Mohammad QD. Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol 2019;6:324-32. [PMID: 30847364 DOI: 10.1002/acn3.706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
110 Peric S, Basta I, Bozovic I, Berisavac I, Stojiljkovic-tamas O, Rajic S, Dominovic-kovacevic A, Stojanov A, Djordjevic G, Jovanovic D. Recurrent Guillain-Barré syndrome – Case series. Neurol India 2019;67:1536. [DOI: 10.4103/0028-3886.273649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Samantaray A, Thota B, Mukkara M, Mohan A, Vengamma B. A study of clinical presentation and outcome of patients with Guillain–Barré syndrome: A prospective observational study at a tertiary care teaching hospital. J Clin Sci Res 2019;8:182. [DOI: 10.4103/jcsr.jcsr_93_19] [Reference Citation Analysis]
112 Hafsteinsdóttir B, Ólafsson E, Jakobsson F. Incidence and outcome of Guillain-Barré syndrome in Iceland: A population-based study. Acta Neurol Scand 2018;138:454-8. [PMID: 30019469 DOI: 10.1111/ane.13000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
113 Huzmeli ED, Korkmaz NC, Duman T, Gokcek O. Effects of sensory deficits on balance, functional status and trunk control in patients diagnosed with guillain-barre syndrome. Neurosciences (Riyadh) 2018;23:301-7. [PMID: 30351287 DOI: 10.17712/nsj.2018.4.20180098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
114 Güzey Aras Y, Doğan Güngen B. Seasonal characteristics and clinical treatment in the Guillaine-Barré syndrome 63 evaluation of the patient series. Ortadogu Tıp Derg 2018;10:284-288. [DOI: 10.21601/ortadogutipdergisi.332864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Islam B, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD. Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study. BMJ Open 2018;8:e022862. [PMID: 30121613 DOI: 10.1136/bmjopen-2018-022862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
116 Axelsson M, Sjögren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Acta Neurol Scand 2018;138:143-50. [PMID: 29624650 DOI: 10.1111/ane.12927] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
117 Gao Y, Zhang HL, Xin M, Wang D, Zheng N, Wang S, Xu J, Wang Y, Zhu J, Feng J. Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression. Biomed Res Int 2018;2018:5703279. [PMID: 30013984 DOI: 10.1155/2018/5703279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
118 Chafale VA, Pandit A, Lahoti SA, Kundu T, Ganguly G. Guillain–Barré Syndrome: Profile of 120 Patients with respect to Response to Various Modalities of Treatment. Indian Journal of Physical Medicine and Rehabilitation 2018;29:31-36. [DOI: 10.5005/jp-journals-10066-0022] [Reference Citation Analysis]
119 Ethemoglu O, Calik M. Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with Guillain-Barré syndrome. Neuropsychiatr Dis Treat 2018;14:1255-60. [PMID: 29805261 DOI: 10.2147/NDT.S162896] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
120 GeurtsvanKessel CH, Islam Z, Islam MB, Kamga S, Papri N, van de Vijver DAMC, Reusken C, Mogling R, Heikema AP, Jahan I, Pradel FK, Pavlicek RL, Mohammad QD, Koopmans MPG, Jacobs BC, Endtz HP. Zika virus and Guillain-Barré syndrome in Bangladesh. Ann Clin Transl Neurol 2018;5:606-15. [PMID: 29761123 DOI: 10.1002/acn3.556] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
121 Shrivastava M, Nehal S, Seema N. Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India. Indian J Med Res 2017;145:203-8. [PMID: 28639596 DOI: 10.4103/ijmr.IJMR_995_14] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
122 Dijkland SA, Voormolen DC, Venema E, Roozenbeek B, Polinder S, Haagsma JA, Nieboer D, Chalos V, Yoo AJ, Schreuders J, van der Lugt A, Majoie CBLM, Roos YBWEM, van Zwam WH, van Oostenbrugge RJ, Steyerberg EW, Dippel DWJ, Lingsma HF; MR CLEAN Investigators. Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study. Stroke 2018;49:965-71. [PMID: 29535271 DOI: 10.1161/STROKEAHA.117.020194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
123 Batista João R. Letter to editor: Dysgeusia as an initial manifestation of Miller-Fisher syndrome. JNSK 2018;8. [DOI: 10.15406/jnsk.2018.08.00282] [Reference Citation Analysis]
124 Yang Y, Lu J, Bao H. Serial electromyographic findings in Guillain-Barré syndrome patients. Eur J Inflamm 2018;16:205873921879353. [DOI: 10.1177/2058739218793536] [Reference Citation Analysis]
125 Guan Z, Shang L, Zhang W, Guo Y, Xue Y, Li X, Gong Y, Liu X. A rating scale for the severity of Guillain-Barré syndrome. Acta Neurol Scand 2017;136:680-7. [PMID: 28612931 DOI: 10.1111/ane.12786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Wang Y, Shang P, Xin M, Bai J, Zhou C, Zhang HL. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. BMC Neurol 2017;17:200. [PMID: 29157205 DOI: 10.1186/s12883-017-0982-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
127 Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD. Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study. Pilot Feasibility Stud 2017;3:40. [PMID: 28975040 DOI: 10.1186/s40814-017-0185-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
128 Wang Y, Lang W, Zhang Y, Ma X, Zhou C, Zhang HL. Long-term prognosis of Guillain-Barré syndrome not determined by treatment options? Oncotarget 2017;8:79991-80001. [PMID: 29108381 DOI: 10.18632/oncotarget.20620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
129 Styczynski AR, Malta JMAS, Krow-Lucal ER, Percio J, Nóbrega ME, Vargas A, Lanzieri TM, Leite PL, Staples JE, Fischer MX, Powers AM, Chang GJ, Burns PL, Borland EM, Ledermann JP, Mossel EC, Schonberger LB, Belay EB, Salinas JL, Badaro RD, Sejvar JJ, Coelho GE. Increased rates of Guillain-Barré syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis 2017;11:e0005869. [PMID: 28854206 DOI: 10.1371/journal.pntd.0005869] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 11.0] [Reference Citation Analysis]
130 Tang HY, Chiu DT, Lin JF, Huang CY, Chang KH, Lyu RK, Ro LS, Kuo HC, Cheng ML, Chen CM. Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome. Sci Rep 2017;7:8140. [PMID: 28811529 DOI: 10.1038/s41598-017-08338-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
131 Nomura K, Kusunoki S, the Research Group of IVIG for GBS in Japan. Japanese multicenter clinical trial of intravenous polyethylene glycol-treated immunoglobulin and comparison with previous clinical trial of sulfonated immunoglobulin in Guillain-Barré syndrome. Clin Exp Neuroimmunol 2017;8:258-266. [DOI: 10.1111/cen3.12407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Li X, Xiao J, Ding Y, Xu J, Li C, He Y, Zhai H, Xie B, Hao J. Clinical and electrophysiological features of post-traumatic Guillain-Barré syndrome. BMC Neurol 2017;17:142. [PMID: 28750621 DOI: 10.1186/s12883-017-0919-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
133 Verma SK, Kumar V, Yadav PS, Joge NKP, Misra R. ASSESSMENT OF SERUM LIPID PROFILE AS PROGNOSTIC MARKER IN CIRRHOSIS OF LIVER - A CROSS SECTIONAL STUDY. jebmh 2017;4:3531-3534. [DOI: 10.18410/jebmh/2017/704] [Reference Citation Analysis]
134 Nayak R. Practical approach to the patient with acute neuromuscular weakness. World J Clin Cases 2017; 5(7): 270-279 [PMID: 28798922 DOI: 10.12998/wjcc.v5.i7.270] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
135 Barzegar M, Toopchizadeh V, Maher MHK, Sadeghi P, Jahanjoo F, Pishgahi A. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. Pediatr Res 2017;82:333-9. [PMID: 28422939 DOI: 10.1038/pr.2017.67] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
136 Roodbol J, de Wit MY, van den Berg B, Kahlmann V, Drenthen J, Catsman-Berrevoets CE, Jacobs BC. Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria. J Neurol 2017;264:856-61. [PMID: 28251358 DOI: 10.1007/s00415-017-8429-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
137 Demirci S, Arslan A, Yürekli VA, Kutluhan S, Koyuncuoğlu HR, Demirci S. P-wave dispersion in patients with Guillain-Barré syndrome. Acta Neurol Belg 2017;117:289-93. [PMID: 27807759 DOI: 10.1007/s13760-016-0717-z] [Reference Citation Analysis]
138 Zhang B, Wu X, Shen D, Li T, Li C, Mao M, Zhang HL, Liu K. The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome. Medicine (Baltimore) 2017;96:e5848. [PMID: 28072747 DOI: 10.1097/MD.0000000000005848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
139 Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 2017;1:CD010369. [PMID: 28084646 DOI: 10.1002/14651858.CD010369.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
140 Ramakrishnan S, Mustare V, Philip M, Thennarasu K, Periyavan S. Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis. Ann Indian Acad Neurol 2017;20:372-7. [PMID: 29184340 DOI: 10.4103/aian.AIAN_242_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
141 Sadek AA, Abou-Taleb A, Ali WA. Outcome of Guillain - Barré Syndrome in Children: A prospective cohort study in a tertiary hospital in Upper Egypt. Electron Physician 2016;8:3318-24. [PMID: 28163843 DOI: 10.19082/3318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
142 Ogna A, Prigent H, Lejaille M, Samb P, Sharshar T, Annane D, Lofaso F, Orlikowski D. Swallowing and swallowing-breathing interaction as predictors of intubation in Guillain-Barré syndrome. Brain Behav 2017;7:e00611. [PMID: 28239521 DOI: 10.1002/brb3.611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
143 Ellrichmann G, Gold R, Ayzenberg I, Yoon MS, Schneider-Gold C. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. Ther Adv Neurol Disord 2017;10:91-101. [PMID: 28382108 DOI: 10.1177/1756285616679369] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
144 Pritchard J, Hughes RA, Hadden RD, Brassington R. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016;11:CD008630. [PMID: 27846348 DOI: 10.1002/14651858.CD008630.pub4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
145 Kusunoki S. History of Guillain-Barré syndrome. Clin Exp Neuroimmunol 2016;7:305-311. [DOI: 10.1111/cen3.12339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
146 Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016;10:CD001446. [PMID: 27775812 DOI: 10.1002/14651858.CD001446.pub5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
147 do Rosário MS, de Jesus PA, Vasilakis N, Farias DS, Novaes MA, Rodrigues SG, Martins LC, Vasconcelos PF, Ko AI, Alcântara LC, de Siqueira IC. Guillain-Barré Syndrome After Zika Virus Infection in Brazil. Am J Trop Med Hyg 2016;95:1157-60. [PMID: 27645785 DOI: 10.4269/ajtmh.16-0306] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
148 Sung EJ, Kim DY, Chang MC, Ko EJ. Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome. Ann Rehabil Med 2016;40:481-8. [PMID: 27446785 DOI: 10.5535/arm.2016.40.3.481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
149 Hosokawa T, Nakajima H, Unoda K, Yamane K, Doi Y, Ishida S, Kimura F, Hanafusa T. Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria. J Neurol 2016;263:1709-18. [PMID: 27278064 DOI: 10.1007/s00415-016-8192-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
150 Fokkink WJ, Haarman AE, Tio-Gillen AP, van Rijs W, Huizinga R, van Doorn PA, Jacobs BC. Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. Ann Clin Transl Neurol 2016;3:547-51. [PMID: 27386503 DOI: 10.1002/acn3.307] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
151 Wu X, Shen D, Li T, Zhang B, Li C, Mao M, Zhao J, Liu K, Zhang HL. Distinct Clinical Characteristics of Pediatric Guillain-Barré Syndrome: A Comparative Study between Children and Adults in Northeast China. PLoS One 2016;11:e0151611. [PMID: 26974666 DOI: 10.1371/journal.pone.0151611] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
152 Zhang DQ, Wang R, Li T, Zhou JP, Chang GQ, Zhao N, Yang LN, Zhai H, Yang L. Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome. Sci Rep 2016;6:21890. [PMID: 26902096 DOI: 10.1038/srep21890] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
153 Che Y, Qiu J, Jin T, Yin F, Li M, Jiang Y. Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome. Sci Rep 2016;6:20963. [PMID: 26865046 DOI: 10.1038/srep20963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
154 Wang Y, Li G, Yang S, Gu X, Li X, Liu M, Wu X, Guan Y, Press R, Zhu J, Zhang HL. Fasting Glucose Levels Correlate with Disease Severity of Guillain-Barré Syndrome. PLoS One 2015;10:e0145075. [PMID: 26684748 DOI: 10.1371/journal.pone.0145075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
155 Tracy JA, Dyck PJB. Peripheral nerve disorders. Evidence-Based Neurology: Management of Neurological Disorders 2015. [DOI: 10.1002/9781119067344.ch22] [Reference Citation Analysis]
156 Feldman EL, Hughes RA, Willison HJ. Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin. Nat Rev Neurol 2015;11:646-50. [PMID: 26458287 DOI: 10.1038/nrneurol.2015.192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
157 Sudulagunta SR, Sodalagunta MB, Sepehrar M, Khorram H, Bangalore Raja SK, Kothandapani S, Noroozpour Z, Aheta Sham M, Prasad N, Sunny SP, Mohammed MD, Gangadharappa R, Nidsale Sudarshan R. Guillain-Barré syndrome: clinical profile and management. Ger Med Sci 2015;13:Doc16. [PMID: 26421004 DOI: 10.3205/000220] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
158 Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, Kuwahara M, Suzuki H, Kusunoki S, Fujimoto Y, Ikezoe K, Kishida H, Tanaka F, Matsushita T, Murai H, Kira J. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015;2:960-71. [PMID: 26478896 DOI: 10.1002/acn3.248] [Cited by in Crossref: 123] [Cited by in F6Publishing: 124] [Article Influence: 15.4] [Reference Citation Analysis]
159 Wang YZ, Lv H, Shi QG, Fan XT, Li L, Yi Wong AH, Hao YL, Si CP, Li CL, Yuki N. Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. Sci Rep 2015;5:13931. [PMID: 26355080 DOI: 10.1038/srep13931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
160 Wu X, Li C, Zhang B, Shen D, Li T, Liu K, Zhang HL. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome. Crit Care 2015;19:310. [PMID: 26330143 DOI: 10.1186/s13054-015-1037-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
161 Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China. PLoS One 2015;10:e0133520. [PMID: 26200903 DOI: 10.1371/journal.pone.0133520] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
162 Deng Y, Ma XJ, Peng W, Sanvito L; Cochrane Neuromuscular Group. Acupuncture for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd007797.pub2] [Reference Citation Analysis]
163 Matsumoto H, Hanajima R, Terao Y, Hashida H, Ugawa Y. Cauda equina conduction time in Guillain-Barré syndrome. J Neurol Sci 2015;351:187-90. [PMID: 25770878 DOI: 10.1016/j.jns.2015.02.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
164 Nagamine S, Fujiwara Y, Shimizu T, Kawata A, Wada K, Isozaki E, Kabuta T. Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain-Barré syndrome. Neurol Sci 2015;36:921-6. [PMID: 25739945 DOI: 10.1007/s10072-015-2137-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
165 Bhargava A, Banakar BF, Pujar GS, Khichar S. A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication. J Neurosci Rural Pract 2014;5:S43-7. [PMID: 25540538 DOI: 10.4103/0976-3147.145200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
166 Deng C. Retrospective Assessment of Non-Inferiority in the Rare Disease, Guillain–Barre Syndrome. BBIJ 2014;1. [DOI: 10.15406/bbij.2014.01.00009] [Reference Citation Analysis]
167 Fu Liong H, Santhi DP, Shanthi V, Mohd Hanip R. Myanmarese Neuropathy: Clinical Description of Acute Peripheral Neuropathy Detected among Myanmarese Refugees in Malaysia. Int Sch Res Notices 2014;2014:187823. [PMID: 27350989 DOI: 10.1155/2014/187823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
168 Hou HQ, Miao J, Feng XD, Han M, Song XJ, Guo L. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin. BMC Neurol 2014;14:202. [PMID: 25315010 DOI: 10.1186/s12883-014-0202-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
169 Nyati KK, Prasad KN. Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome. Mediators Inflamm 2014;2014:758639. [PMID: 25614713 DOI: 10.1155/2014/758639] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
170 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014;:CD002063. [PMID: 25238327 DOI: 10.1002/14651858.CD002063.pub6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 138] [Article Influence: 10.0] [Reference Citation Analysis]
171 Shimizu F, Sawai S, Sano Y, Beppu M, Misawa S, Nishihara H, Koga M, Kuwabara S, Kanda T. Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS One 2014;9:e104205. [PMID: 25105500 DOI: 10.1371/journal.pone.0104205] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
172 Wu X, Wu W, Wang Z, Shen D, Pan W, Wang Y, Wu L, Wu X, Feng J, Liu K, Zhu J, Zhang HL. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. PLoS One 2014;9:e104074. [PMID: 25084153 DOI: 10.1371/journal.pone.0104074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
173 Naik KR, Saroja AO, Mahajan M. Intact thumb reflex in areflexic Guillain Barré syndrome: A novel phenomenon. Ann Indian Acad Neurol 2014;17:199-201. [PMID: 25024572 DOI: 10.4103/0972-2327.132628] [Reference Citation Analysis]
174 van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82. [DOI: 10.1038/nrneurol.2014.121] [Cited by in Crossref: 525] [Cited by in F6Publishing: 556] [Article Influence: 58.3] [Reference Citation Analysis]
175 Sung JY, Tani J, Park SB, Kiernan MC, Lin CS. Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain 2014;137:2155-63. [PMID: 24983276 DOI: 10.1093/brain/awu158] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
176 Li S, Jin T, Zhang HL, Yu H, Meng F, Concha Quezada H, Zhu J. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments. Mediators Inflamm 2014;2014:740947. [PMID: 24899787 DOI: 10.1155/2014/740947] [Cited by in Crossref: 35] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
177 Kim JK, Bae JS, Kim DS, Kusunoki S, Kim JE, Kim JS, Park YE, Park KJ, Song HS, Kim SY, Lim JG, Kim NH, Suh BC, Nam TS, Park MS, Choi YC, Sohn EH, Na SJ, Huh SY, Kwon O, Lee SY, Lee SH, Oh SY, Jeong SH, Lee TK, Kim DU. Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study. J Clin Neurol 2014;10:94-100. [PMID: 24829594 DOI: 10.3988/jcn.2014.10.2.94] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
178 Karaca S, Kozanoğlu İ, Karakurum Göksel B, Karataş M, Tan M, Yerdelen VD, Giray S, Arlier Z. Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years. Noro Psikiyatr Ars 2014;51:63-8. [PMID: 28360597 DOI: 10.4274/npa.y6879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
179 Kinboshi M, Inoue M, Kojima Y, Ono M, Nakagawa T, Kanda M, Shibasaki H. Pain in the acute phase of Guillain-Barré syndrome. Neurol Clin Neurosci 2014;2:50-53. [DOI: 10.1111/ncn3.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Odaka M, Yuki N. Variants and differential diagnosis of Guillain–Barré syndrome. Expert Review of Neurotherapeutics 2014;2:877-89. [DOI: 10.1586/14737175.2.6.877] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
181 Piccione EA, Salame K, Katirji B. Guillain-Barré Syndrome and Related Disorders. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_28] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
182 Rosenfeld J, Jackson CE. Outcome Measures and Clinical Assessment Instruments in Neuromuscular Disease. Neuromuscular Disorders in Clinical Practice 2014. [DOI: 10.1007/978-1-4614-6567-6_15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Rinaldi S, Brennan KM, Kalna G, Walgaard C, van Doorn P, Jacobs BC, Yu RK, Mansson JE, Goodyear CS, Willison HJ. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS One 2013;8:e82337. [PMID: 24358172 DOI: 10.1371/journal.pone.0082337] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
184 Samadi M, Kazemi B, Golzari Oskoui S, Barzegar M. Assessment of autonomic dysfunction in childhood guillain-barré syndrome. J Cardiovasc Thorac Res 2013;5:81-5. [PMID: 24252981 DOI: 10.5681/jcvtr.2013.018] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
185 Li C, Zhao P, Sun X, Che Y, Jiang Y. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome. Mediators Inflamm 2013;2013:639712. [PMID: 24174711 DOI: 10.1155/2013/639712] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
186 González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol 2013;13:95. [PMID: 23876199 DOI: 10.1186/1471-2377-13-95] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
187 Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:299-326. [PMID: 22850724 DOI: 10.2183/pjab.88.299] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
188 Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31:491-510. [PMID: 23642721 DOI: 10.1016/j.ncl.2013.01.005] [Cited by in Crossref: 191] [Cited by in F6Publishing: 202] [Article Influence: 19.1] [Reference Citation Analysis]
189 Matsushita M, Kitoh H, Itomi K, Kitakoji T, Iwata K, Mishima K, Ishiguro N, Hattori T. Orthopaedic manifestations and diagnostic clues in children with Guillain-Barré syndrome. J Child Orthop 2013;7:177-82. [PMID: 23755090 DOI: 10.1007/s11832-012-0475-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
190 Fujimura H. The Guillain-Barré syndrome. Handb Clin Neurol 2013;115:383-402. [PMID: 23931791 DOI: 10.1016/B978-0-444-52902-2.00021-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
191 Nakamura H, Endo M, Sugawara E, Kuwahara M, Kusunoki S, Tanaka F, Takahashi T. A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity. Rinsho Shinkeigaku 2013;53:799-802. [DOI: 10.5692/clinicalneurol.53.799] [Reference Citation Analysis]
192 Akbayram S, Doğan M, Akgün C, Peker E, Sayιn R, Aktar F, Bektaş MS, Caksen H. Clinical features and prognosis with Guillain-Barré syndrome. Ann Indian Acad Neurol 2011;14:98-102. [PMID: 21808470 DOI: 10.4103/0972-2327.82793] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
193 Li S, Yu M, Li H, Zhang H, Jiang Y. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome. Mediators Inflamm 2012;2012:260473. [PMID: 23091305 DOI: 10.1155/2012/260473] [Cited by in Crossref: 47] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
194 Sarkar UK, Menon L, Sarbapalli D, Pal R, Zaman FA, Kar S, Singh J, Mondal M, Mukherjee S. Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata. J Nat Sci Biol Med 2011;2:211-5. [PMID: 22346239 DOI: 10.4103/0976-9668.92320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Wang XK, Zhang HL, Meng FH, Chang M, Wang YZ, Jin T, Mix E, Zhu J. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome. Neurol Sci 2013;34:655-61. [PMID: 22526766 DOI: 10.1007/s10072-012-1092-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
196 Naphade PU, Verma R, Garg RK, Singh M, Malhotra HS, Shankwar SN. Prevalence of bladder dysfunction, urodynamic findings, and their correlation with outcome in Guillain-Barre syndrome. Neurourol Urodyn 2012;31:1135-40. [PMID: 22488834 DOI: 10.1002/nau.22236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
197 Bos Eyssen ME, van Doorn PA, Jacobs BC, Steyerberg EW, van der Voort PH, Zandstra DF, Horn J, Spronk PE, Hoedemaekers CW, Bakker J, van der Jagt M. Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome. Neurocrit Care 2011;15:128-33. [PMID: 21468781 DOI: 10.1007/s12028-011-9536-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
198 Chang KH, Chuang TJ, Lyu RK, Ro LS, Wu YR, Chang HS, Huang CC, Kuo HC, Hsu WC, Chu CC, Chen CM. Identification of gene networks and pathways associated with Guillain-Barré syndrome. PLoS One 2012;7:e29506. [PMID: 22253732 DOI: 10.1371/journal.pone.0029506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
199 Huan M, Smith AG. Weakness (Guillain–Barré Syndrome). Emergency Neurology 2012. [DOI: 10.1007/978-0-387-88585-8_12] [Reference Citation Analysis]
200 Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, Hirata K, Notturno F, Uncini A. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 2012;259:1181-90. [PMID: 22143612 DOI: 10.1007/s00415-011-6330-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 6.0] [Reference Citation Analysis]
201 McMillan HJ, Darras BT, Kang PB. Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol 2011;13:590-607. [PMID: 21912840 DOI: 10.1007/s11940-011-0146-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
202 Ehling R, Pauli FD, Lackner P, Kuenz B, Santner W, Lutterotti A, Gneiss C, Hegen H, Schocke M, Deisenhammer F, Berger T, Reindl M. Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis. Fluids Barriers CNS 2011;8:25. [PMID: 22029888 DOI: 10.1186/2045-8118-8-25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
203 Grimaldi-Bensouda L, Alpérovitch A, Besson G, Vial C, Cuisset JM, Papeix C, Lyon-Caen O, Benichou J, Rossignol M; Lucien Abenhaim for the GBS-PGRx Study Group. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 2011;174:326-35. [PMID: 21652600 DOI: 10.1093/aje/kwr072] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
204 El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011;15:R164. [PMID: 21745374 DOI: 10.1186/cc10305] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
205 Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011;76:968-75. [PMID: 21403108 DOI: 10.1212/WNL.0b013e3182104407] [Cited by in Crossref: 174] [Cited by in F6Publishing: 178] [Article Influence: 14.5] [Reference Citation Analysis]
206 Winters JL. Hemapheresis. Henry's Clinical Diagnosis and Management by Laboratory Methods 2011. [DOI: 10.1016/b978-1-4377-0974-2.00037-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
207 Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
208 Deng Y, Ma XJ, Peng W, Sanvito L. Acupuncture for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2009. [DOI: 10.1002/14651858.cd007797] [Reference Citation Analysis]
209 Hahn CD, Banwell BL. Diseases of the Peripheral Nervous System. The Central Nervous System in Pediatric Critical Illness and Injury 2009. [DOI: 10.1007/978-1-84800-993-6_12] [Reference Citation Analysis]
210 Gold R, Müllges W, Hansen H-, Anetseder M, Metterlein T, Müller R, Hund E, Winterholler M, Toyka KV. Neuromuskuläre Erkrankungen. NeuroIntensiv. [DOI: 10.1007/978-3-540-68317-9_40] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
211 Wanschitz J, Ehling R, Löscher WN, Künz B, Deisenhammer F, Kuhle J, Budka H, Reindl M, Berger T. Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome. J Neurol 2008;255:917-24. [PMID: 18712293 DOI: 10.1007/s00415-008-0815-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
212 Mori I, Parizot C, Dorgham K, Demeret S, Amoura Z, Bolgert F, Gorochov G. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome. PLoS One 2008;3:e2109. [PMID: 18461177 DOI: 10.1371/journal.pone.0002109] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
213 Kushnir M, Klein C, Pollak L, Rabey JM. Evolving pattern of Guillain-Barre syndrome in a community hospital in Israel. Acta Neurol Scand 2008;117:347-50. [PMID: 17995988 DOI: 10.1111/j.1600-0404.2007.00949.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
214 Kaynar L, Altuntas F, Aydogdu I, Turgut B, Kocyigit I, Hacioglu SK, Ismailogullari S, Turgut N, Erkurt MA, Sari I, Oztekin M, Solmaz M, Eser B, Ersoy AO, Unal A, Cetin M. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 2008;38:109-15. [PMID: 18331814 DOI: 10.1016/j.transci.2007.11.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
215 Davis LE. Nervous System Complications of Systemic Viral Infections. Neurology and General Medicine 2008. [DOI: 10.1016/b978-044306707-5.50047-x] [Reference Citation Analysis]
216 Ralph JW, Aminoff MJ. Neuromuscular Complications of General Medical Disorders. Neurology and General Medicine 2008. [DOI: 10.1016/b978-044306707-5.50063-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Hughes R, Feldman EL, Bland JD. Peripheral Nerve Disorders. Evidence-based Neurology: Management of Neurological Disorders 2007. [DOI: 10.1002/9780470988350.ch23] [Reference Citation Analysis]
218 Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran. BMC Neurol 2007;7:22. [PMID: 17683586 DOI: 10.1186/1471-2377-7-22] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
219 Katirji B. Case 23. Electromyography in Clinical Practice 2007. [DOI: 10.1016/b978-0-323-02899-8.50032-x] [Reference Citation Analysis]
220 Saito K, Masuda Y, Imaizumi H, Nawa Y, Iwayama Y, Kuroda H, Imai T, Asai Y. Sequential measurement of nerve conduction velocity is a valid method for the evaluation of therapeutic efficacy in severe Guillain-Barr^|^eacute; syndrome: report of a case. Nihon Shuchu Chiryo Igakukai zasshi 2007;14:203-206. [DOI: 10.3918/jsicm.14.203] [Reference Citation Analysis]
221 Nomura K. 16. Immunoglobulin Therapy for Neurologic Diseases. J Jpn Soc Intern Med 2007;96:2046-2053. [DOI: 10.2169/naika.96.2046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Ann Saudi Med 2006;26:22-7. [PMID: 16521871 DOI: 10.5144/0256-4947.2006.22] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
223 Benatar M. Guillain-Barré Syndrome. Neuromuscular Disease 2006. [DOI: 10.1007/978-1-59745-106-2_11] [Reference Citation Analysis]
224 Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile-Orazio E. Long term disability and social status change after Guillain-Barré syndrome. J Neurol 2006;253:214-8. [PMID: 16096809 DOI: 10.1007/s00415-005-0958-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
225 Peltier A, Russell J. Acute Inflammatory Demyelinating Polyradiculoneuropathy (Guillain–Barre´ Syndrome). Neurological Disease and Therapy 2005. [DOI: 10.1201/b14157-11] [Reference Citation Analysis]
226 Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand 2004;109:71-4. [PMID: 14653854 DOI: 10.1034/j.1600-0404.2003.00179.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
227 Hughes RA. Treating nerves: from anecdote to systematic review. J R Soc Med 2003;96:432-5. [PMID: 12949197 DOI: 10.1258/jrsm.96.9.432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
228 Aksu S, Karakaya İ, Karakaya MG, Kilinç M, Tan E. Combined physiotherapy program results on musculoskeletal pain in neuro-muscular diseases. The Pain Clinic 2003;15:287-291. [DOI: 10.1163/156856903767650817] [Reference Citation Analysis]
229 Dourado ME, Duarte RC, Ferreira LC, Queiroz JW, Illa I, Perez-Perez G, Guerrant RL, Jerônimo SM. Anti-ganglioside antibodies and clinical outcome of patients with Guillain-Barré Syndrome in northeast Brazil. Acta Neurol Scand 2003;108:102-8. [PMID: 12859286 DOI: 10.1034/j.1600-0404.2003.00103.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
230 Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA; Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601. [PMID: 11971045 DOI: 10.1136/jnnp.72.5.596] [Cited by in Crossref: 214] [Cited by in F6Publishing: 223] [Article Influence: 10.2] [Reference Citation Analysis]
231 Hennen G, Jörg J. Erkrankungen des peripheren Nervensystems. Neurologische Therapie 2002. [DOI: 10.1007/978-3-642-56398-0_21] [Reference Citation Analysis]
232 Saraf S, Singh RK. GB Syndrome with Herpes simplex infection. Indian J Pediatr 2001;68:889-890. [DOI: 10.1007/bf02762121] [Reference Citation Analysis]
233 Bril V. Peripheral Neuropathies: Experience with Large Multicentre Trials. Clinical Trials in Neurology 2001. [DOI: 10.1007/978-1-4471-3787-0_37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
234 Klein C, Polydefkis M, Chaudhry V. Chapter 13 Peripheral Neuropathy Treatment Trials. Clinical Trials in Neurologic Practice. Elsevier; 2001. pp. 261-91. [DOI: 10.1016/s1877-3419(09)70020-0] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
235 Prendergast MM, Moran AP. Review: Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. Journal of Endotoxin Research 2000;6:341-359. [DOI: 10.1177/09680519000060050501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
236 Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1999;67:433-8. [PMID: 10486387 DOI: 10.1136/jnnp.67.4.433] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 2.8] [Reference Citation Analysis]
237 Raphael J, Chevret S, Jars-guincestre M, Bolgert F, Gajdos P. Prise en charge des patients atteints d'un syndrome de Guillain-Barré de l'adulte: proposition d'une stratégie thérapeutique. Réanimation Urgences 1998;7:571-579. [DOI: 10.1016/s1164-6756(99)80006-1] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
238 Dourado ME, Freitas MLD, Santos FMD. Síndrome de Guillain-Barré com flutuações relacionadas ao tratamento com imunoglobulina humana endovenosa (curso trifásico): relato de caso. Arq Neuro-Psiquiatr 1998;56:476-479. [DOI: 10.1590/s0004-282x1998000300020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
239 Créange A, Bélec L, Clair B, Degos JD, Raphaël JC, Gherardi RK. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998;64:162-5. [PMID: 9489524 DOI: 10.1136/jnnp.64.2.162] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 1.4] [Reference Citation Analysis]
240 Vajsar J, Ozon A, Topaloglu H. Letters. European Journal of Paediatric Neurology 1998;2:58-59. [DOI: 10.1016/1090-3798(98)80055-x] [Reference Citation Analysis]
241 Raphael J, Chevret S, Auriant I, Sharshar T, Bouget J, Bolgert F. Les traitements du syndrome de Guillain-Barré de l'adulte: place des échanges plasmatiques. La Revue de Médecine Interne 1998;19:60-68. [DOI: 10.1016/s0248-8663(97)83702-2] [Reference Citation Analysis]
242 Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500. [PMID: 9343130 DOI: 10.1136/jnnp.63.4.494] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 3.2] [Reference Citation Analysis]
243 Guérin C. New Trends in the Treatment of Advanced Neurological Disease Condition — Guillain-Barré Syndrome. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E. 1997. [DOI: 10.1007/978-88-470-2296-6_42] [Reference Citation Analysis]
244 Busse O, Jörg J, Rumpl E, Krauseneck P, Besser R, Schwalen S, Prange HW, Hartung H, Hennen G, Rohkamm R, Grotemeyer K, Rieß O. Therapie der einzelnen Krankheitsbilder. Neurologische Therapie 1997. [DOI: 10.1007/978-3-642-97934-7_3] [Reference Citation Analysis]
245 Howlett WP, Vedeler CA, Nyland H, Aarli JA. Guillain-Barré syndrome in northern Tanzania: a comparison of epidemiological and clinical findings with western Norway. Acta Neurol Scand 1996;93:44-9. [PMID: 8825272 DOI: 10.1111/j.1600-0404.1996.tb00169.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
246 Rostami AM. Guillain-Barré syndrome: clinical and immunological aspects. Immunoneurology 1996. [DOI: 10.1007/978-3-642-61191-9_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
247 Molenaar DS, de Haan R, Vermeulen M. Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies. J Neurol Neurosurg Psychiatry 1995;59:165-9. [PMID: 7629531 DOI: 10.1136/jnnp.59.2.165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
248 Beghi E, The Italian Guillain-Barré Study Group. Audit of care of acute inflammatory polyradiculoneuropathy in Italy. Pharmacoepidem Drug Safe 1995;4:137-146. [DOI: 10.1002/pds.2630040306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
249 Hunt D, Lang J, Cook DJ. Guillain-Barré Syndrome in the 1990’s. Yearbook of Intensive Care and Emergency Medicine 1995. [DOI: 10.1007/978-3-642-79154-3_77] [Reference Citation Analysis]
250 Hughes R. Dexamethasone treatment of rats receiving a sciatic nerve crush injury markedly diminished adherence of PC12 cells to a longitudinal section of the crushed sciatic nerve. J Neuroimmunol 1994;52:219. [PMID: 8034761 DOI: 10.1016/0165-5728(94)90116-3] [Reference Citation Analysis]
251 Hughes RA, Bihari D. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry 1993;56:334-43. [PMID: 8482951 DOI: 10.1136/jnnp.56.4.334] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 1.5] [Reference Citation Analysis]
252 Leshner RT, Teasley JE. Pediatric Neuromuscular Emergencies. Neurologic Emergencies in Infancy and Childhood 1993. [DOI: 10.1016/b978-0-7506-9419-3.50019-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
253 Gordon N. Disorders and diseases of the motor system. Neurological Problems in Childhood 1993. [DOI: 10.1016/b978-0-7506-0898-5.50013-4] [Reference Citation Analysis]
254 Gibbels E, Giebisch U. Natural course of acute and chronic monophasic inflammatory demyelinating polyneuropathies (IDP). A retrospective analysis of 266 cases. Acta Neurol Scand 1992;85:282-91. [PMID: 1316709 DOI: 10.1111/j.1600-0404.1992.tb04045.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
255 Winer J. Guillain-Barré syndrome revisited. BMJ 1992;304:65-6. [PMID: 1737137 DOI: 10.1136/bmj.304.6819.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
256 Kühne I, Ceballos-baumann AO, Conrad B, Kruggel F, von Einsiedel HG, Schneider R, Kluge R, Willmes K, Stephan KM, Netz J, Hömberg V, Schönle PW, Schwall D, Bischoff C, Machetanz J, Meyer B, Pallmann F, Ohlmann D, Krick C, Jäger H, Nachtigall W, Schimrigk K, Machetanz J, Forster J, Meyer BU, Bresser B, Thomas W, Schmitt RM, Mielke U, Welsch HJ, Lagler E, Dillmann U, Krämer G, Lüder G, Hopf HC, Haupt WF, Borberg H, Rosenow F, Stoll M, Hamann G, Schimrigk K, Donauer E, Steudel WI, Elek JM, Orfgen T, Sieb JP, Dengler R, Hamann G, Strittmatter M, Holzer G, Haaß A, Schimrigk K, Rosenow F, Haupt WF, Rose A, Borberg H, Westarp ME, Flügel RM, Bartmann P, Fuchs D, Hoff-jörgensen R, Clausen D, Westarp MP, Kornhuber HH, Westphal KP, Bauer J, Laupheimer H, Westarp ME, Hülser P, Schreiber H, Baumgärtner K, Wollinsky KH, van Eick H, Kornhuber HH, Heidenreich F, Leifeld L, Benecke R, Jost WH, Schimrigk K, Bergemann N, Baas H, Demisch L, Fischer P, Alesch° F, Fertl E, Auff E, Koos W, Bauer B, Schmidt B, Grau G, Henschel S, Braus DF, Schwechheimer K, Volk B, Claus D, Beck E, Gmeiner HJ, Puschmann E, Brunhölzl C, Jäger W, Neundörfer B, Seitz RJ, Schlaug G, Kleinschmidt A, Reifenberger G, Wechsler W, Wirrwar A, Nebeling B, Treede R, Hansen HC, Kunze K, Bufler J, Toyka KV, Maelicke A, Franke C, Melms A, Malcherek G, Link H, Kalbacher H, Lindstrom J, Oksenberg J, Steinman L, Müller C, Platz T, Denzler P, Mauritz K, Binkofski F, Kunesch E, Kuhlmann H, Hefter H, Freund H, Weindl A, Boecker H, Kuwert T, Mayer T, Winkler B, Meyer BU, von Einsiedel HG, Herzog H, Feinendegen LE, Arnold G, Eichhorn T, Mai N, Gasser T, Marquard C, Oertel WH, Werhahn KJ, Fong J, Rothwell JC, Shorvon S, Thompson PD, Marsden CD, Bauer J, Elger CE, Hefner G, Güldenberg V, Meierkord H, Shorvon S, Lightman S, Trimble M, Jaspert A, Claus D, Spitzer A, Grehl H, Neundörfer B, Henningsen H, Pause M, Mundinger F, Schwab J, Grehl H, Jaspert A, Claus D, Neundörfer B, Günther T, Kaendler SH, Enzensberger W, Fischer P, Holzer G, Raitzig M, Müller J, Haaß A, Schimrigk K, Hefner G, Elger CE, Zinner J, Kasper S, Stuerenburg HJ, Hase M, Hinse P, Neunzig P, Kunze K, Weis M, Claus D, Rechlin T, Hilz MJ. Therapy monitoring. Abstracts of the 65th congress of the German Society of Neurology 1992. [DOI: 10.1007/978-3-662-39699-5_4] [Reference Citation Analysis]
257 Loh L. Guillain-Barré Syndrome and Myasthenia Gravis. Care of the Critically Ill Patient 1992. [DOI: 10.1007/978-1-4471-3400-8_59] [Reference Citation Analysis]
258 Raphael JC, Chevret S, Jars-Guincestre MC, Remy-Neris O, Chastang C, Gajdos P. [Guillain-Barré syndrome. Recent clinical and therapeutic aspects]. Rev Med Interne 1991;12:363-8. [PMID: 1771316 DOI: 10.1016/s0248-8663(05)80847-1] [Reference Citation Analysis]
259 Rantala H, Uhari M, Niemelä M. Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome. Arch Dis Child 1991;66:706-8; discussion 708-9. [PMID: 2053793 DOI: 10.1136/adc.66.6.706] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 1.5] [Reference Citation Analysis]
260 Raphael JC, Chevret S, Elkharrat D. Plasma Exchange in the Guillain-Barré Syndrome. Update in Intensive Care and Emergency Medicine 1991. [DOI: 10.1007/978-3-642-84423-2_59] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
261 Raphael JC, Elkharrat D, Chevret S, Vercken JB, Chastang C, Gajdos P. Plasma Exchange and Guillian-Barré Syndrome. Advances in haemapheresis 1991. [DOI: 10.1007/978-1-4615-3904-9_7] [Reference Citation Analysis]
262 Mellits ED, Mckhann GM. Guillain-Barré: Plasmapheresis. Foundations of Neurology 1990. [DOI: 10.1007/978-1-4613-1495-0_17] [Reference Citation Analysis]
263 Miller R, Sheron N, Semple S. Sarcoidosis presenting with an acute Guillain-Barré syndrome. Postgrad Med J 1989;65:765-7. [PMID: 2694139 DOI: 10.1136/pgmj.65.768.765] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 0.8] [Reference Citation Analysis]
264 Genis D, Busquets C, Manubens E, Dávalos A, Baró J, Oterino A. Epidural morphine analgesia in Guillain Barré syndrome. J Neurol Neurosurg Psychiatry 1989;52:999-1001. [PMID: 2795070 DOI: 10.1136/jnnp.52.8.999] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
265 Hennen G, Jörg J. Erkrankungen des peripheren Nervensystems. Spezielle neurologische Therapie 1989. [DOI: 10.1007/978-3-662-00682-5_11] [Reference Citation Analysis]
266 Ohno R, Hamaguchi K, Nomura K, Sowa K, Tanaka H, Negishi T, Yamashita T. Immune responses in experimental allergic neuritis treated with corticosteroids. Acta Neurol Scand 1988;77:468-73. [PMID: 2457290 DOI: 10.1111/j.1600-0404.1988.tb05942.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
267 Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-8. [PMID: 3404161 DOI: 10.1136/jnnp.51.5.613] [Cited by in Crossref: 195] [Cited by in F6Publishing: 212] [Article Influence: 5.6] [Reference Citation Analysis]
268 Osuntokun BO. Epidemiology of Peripheral Neuropathies. Neurology 1986. [DOI: 10.1007/978-3-642-70007-1_36] [Reference Citation Analysis]
269 van der Knaap MS, Derksen RH. Plasma exchange in hands of the neurologist. Clin Neurol Neurosurg 1986;88:233-43. [PMID: 3542334 DOI: 10.1016/s0303-8467(86)80040-3] [Reference Citation Analysis]
270 Hughes RAC. Clinical Trials Relating to Peripheral Neuropathy. Neurology 1986. [DOI: 10.1007/978-3-642-70007-1_45] [Reference Citation Analysis]
271 Hallett M, Tandon D, Berardelli A. Treatment of peripheral neuropathies. J Neurol Neurosurg Psychiatry 1985;48:1193-207. [PMID: 3003254 DOI: 10.1136/jnnp.48.12.1193] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
272 Hughes RA. Plasma exchange for Guillain-Barré syndrome. Br Med J (Clin Res Ed) 1985;291:615-6. [PMID: 3928050 DOI: 10.1136/bmj.291.6496.615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
273 Greenwood RJ, Hughes RAC, Bowden AN, Gordon NS, Millac P, Davis JN, Asian S, Chadwick DW, Mclellan DL, Stott RB. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. J Clin Apheresis 1985;2:343-51. [DOI: 10.1002/jca.2920020420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
274 Segurado O, Krüger H. Immunologische Parameter bei 187 Patienten mit entzündlichen peripheren Neuropathien. Kardiovaskuläre Erkrankungen und Nervensystem Neurotoxikologie Probleme des Hirntodes 1985. [DOI: 10.1007/978-3-642-46521-5_168] [Reference Citation Analysis]
275 PLASMA EXCHANGE IN THE GUILLAIN-BARRÉ SYNDROME. The Lancet 1984;324:1312-1313. [DOI: 10.1016/s0140-6736(84)90826-2] [Reference Citation Analysis]
276 Walls TJ, Ashworth B, Saunders M. Immobilisation hypercalcaemia complicating polyneuropathy in adolescent boys. J Neurol Neurosurg Psychiatry 1984;47:1232-5. [PMID: 6094736 DOI: 10.1136/jnnp.47.11.1232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
277 Bezwoda WR, Fritz V, Reef HE, Staub H, Derman DP, Lewis M, Kallenbach J, Zaltzman M, Naughton MA. Treatment of acute post-infective polyneuropathy by means of plasma exchange. Acta Neurol Scand 1984;69:112-9. [PMID: 6711272 DOI: 10.1111/j.1600-0404.1984.tb07787.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
278 Urbaniak S. 12 Therapeutic Plasma and Cellular Apheresis. Clinics in Haematology 1984;13:217-251. [DOI: 10.1016/s0308-2261(18)30042-0] [Reference Citation Analysis]
279 Hughes RAC. Acute inflammatory polyneuropathy. Contemporary Neurology 1984. [DOI: 10.1016/b978-0-407-00308-8.50034-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
280 Peripheral Neuropathy. N Engl J Med 1982;307:1457-1457. [DOI: 10.1056/nejm198212023072324] [Reference Citation Analysis]
281 Pentland B, Adams GG, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982;45:866-9. [PMID: 6292370 DOI: 10.1136/jnnp.45.10.866] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
282 Kennard C, Newland AC, Ridley A. Treatment of the Guillain-Barré syndrome by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:847-50. [PMID: 7131022 DOI: 10.1136/jnnp.45.9.847] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
283 Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:675-9. [PMID: 7130991 DOI: 10.1136/jnnp.45.8.675] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 0.7] [Reference Citation Analysis]
284 Lovaste MG, Boninsegna C, Girardi P, Ferrari G. Plasmapheresis in acute idiopathic polyradiculoneuritis: Report of 3 cases. Ital J Neuro Sci 1982;3:129-132. [DOI: 10.1007/bf02043945] [Reference Citation Analysis]
285 Kristensen HS. Guillain-Barré syndrome. Intensive Care 1982. [DOI: 10.1007/978-94-009-7313-8_15] [Reference Citation Analysis]
286 Ayyar DR. Neuromuscular Crise. Intensive Care for Neurological Trauma and Disease 1982. [DOI: 10.1016/b978-0-12-788284-0.50036-x] [Reference Citation Analysis]
287 Durward WF, Burnett AK, Watkins R, Reid JM. Plasma exchange in Guillain-Barré syndrome. Br Med J (Clin Res Ed) 1981;283:794. [PMID: 6791753 DOI: 10.1136/bmj.283.6294.794-b] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.2] [Reference Citation Analysis]
288 Valbonesi M, Garelli S, Mosconi L, Manca F, Cantarella S, Celada F. Patients with High Titers of Circulating Immune Complexes are Most Likely to Benefit from Plasmapheresis Treatment. Int J Artif Organs 1981;4:234-237. [DOI: 10.1177/039139888100400508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
289 Felten-papaiconomou A, Colimon R, Laffay J, Guerin J, Ferchal F, Perol Y. Syndrome de guillain-barré compliquant une rougeole. Médecine et Maladies Infectieuses 1981;11:470-4. [DOI: 10.1016/s0399-077x(81)80066-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
290 Maisey DN, Olczak SA. Successful plasmapheresis in the Miller-Fisher syndrome. Br Med J (Clin Res Ed) 1981;282:1159. [PMID: 6786483 DOI: 10.1136/bmj.282.6270.1159-a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
291 Pentland B. Azathioprine in chronic relapsing idiopathic polyneuropathy. Postgrad Med J 1980;56:734-5. [PMID: 6261230 DOI: 10.1136/pgmj.56.660.734] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
292 Swash M. Clinical aspects of Guillian-Barré syndrome: a review. J R Soc Med 1979;72:670-3. [PMID: 552572 DOI: 10.1177/014107687907200909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]